Ondine Biomedical Expands Steriwave Adoption in Quebec Hospitals

The latest update is out from Ondine Biomedical, Inc. ( (GB:OBI) ).

Ondine Biomedical Inc. announced that Hôtel-Dieu de Sherbrooke has adopted its Steriwave nasal photodisinfection as the standard of care for orthopedic surgeries, marking it as the second hospital in Quebec to do so. This adoption follows successful implementation at Hôpital Fleurimont, which reported a significant reduction in surgical site infections. The expansion of Steriwave’s use highlights its efficacy and the growing trend among healthcare institutions to adopt innovative infection prevention technologies, particularly in light of rising antimicrobial resistance. The technology offers a rapid, non-antibiotic solution that does not rely on patient compliance, providing a significant advantage in infection control strategies.

The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary photodisinfection technology, with approvals in Canada, Europe, Australia, Mexico, and other countries. In the United States, its nasal photodisinfection system, Steriwave, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is undergoing clinical trials for regulatory approval.

Average Trading Volume: 132,860

Technical Sentiment Signal: Buy

Current Market Cap: £56.51M

For an in-depth examination of OBI stock, go to TipRanks’ Overview page.